In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a major target in cancer immunotherapy. Now, Dr. Ishida and colleagues ...
The programmed cell death protein-1 (PD-1) pathway constitutes a central regulatory axis in maintaining immune tolerance and preventing self-reactivity. Engagement of PD-1 on T lymphocytes by its ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results